MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone49 89 89927 0
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/7/2019 (Estimated)
OptionableNot Optionable
MorphoSys (NYSE:MOR) Frequently Asked Questions
What is MorphoSys' stock symbol?
MorphoSys trades on the New York Stock Exchange (NYSE) under the ticker symbol "MOR."
How were MorphoSys' earnings last quarter?
MorphoSys AG Unsponsored ADR (NYSE:MOR) issued its earnings results on Tuesday, May, 7th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. The firm earned $15.39 million during the quarter, compared to analyst estimates of $10.34 million. View MorphoSys' Earnings History.
When is MorphoSys' next earnings date?
What is the consensus analysts' recommendation for MorphoSys?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MorphoSys.
Has MorphoSys been receiving favorable news coverage?
Media headlines about MOR stock have been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MorphoSys earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for MorphoSys.
Who are some of MorphoSys' key competitors?
Some companies that are related to MorphoSys include Cronos Group (CRON), Moderna Inc (NASDAQ) (MRNA), BTG (BTG), Abcam (ABC), Clinuvel Pharmaceuticals (CUV), ProMetic Life Sciences (PLI), Genus (GNS), Concordia International (CXR), Polynovo (PNV), Mesoblast (MSB), Resverlogix (RVX), Theratechnologies (TH), Oxford BioMedica (OXB), Starpharma (SPL) and Neptune Wellness Solutions (NEPT).
What other stocks do shareholders of MorphoSys own?
Who are MorphoSys' key executives?
MorphoSys' management team includes the folowing people:
- Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 60)
- Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
- Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
- Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
- Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 61)
When did MorphoSys IPO?
(MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.
How do I buy shares of MorphoSys?
Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MorphoSys' stock price today?
One share of MOR stock can currently be purchased for approximately $24.84.
How big of a company is MorphoSys?
What is MorphoSys' official website?
How can I contact MorphoSys?
The company can be reached via phone at 49 89 89927 0.
MarketBeat Community Rating for MorphoSys (NYSE MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
